Blog
RSS FeedPosted by Michael Wonder on 15 Feb 2021
It’s time to fast track innovation in medical devices for children
11 February 2021 - When a baby arrived at Children’s National Hospital with a critically underdeveloped heart, it was clear ...
Posted by Michael Wonder on 04 Feb 2021
Repurposing of prescription medicines
4 February 2021 - The Therapeutic Goods Administration is conducting a public consultation that seeks to understand potential obstacles and ...
Posted by Michael Wonder on 15 Jan 2021
Funding of pharmaceutical innovation during and after the COVID-19 pandemic
14 January 2021 - The COVID-19 pandemic has highlighted the available mechanisms for funding research, development, manufacturing, and distribution in the ...
Posted by Michael Wonder on 08 Dec 2020
CDER focuses on novel drug development tools to help speed creation of new therapies
7 December 2020 - There are many novel drug development tools that incorporate the latest advances in science and technology but ...
Posted by Michael Wonder on 02 Nov 2020
On the integration of early health technology assessment in the innovation process: reflections from five stakeholders
28 October 2020 - Early health technology assessment, which includes all methods used to inform industry and other stakeholders about the ...
Posted by Michael Wonder on 20 Oct 2020
Health charities and patient groups join together to protect access to breakthrough medical treatments in Canada
19 October 2020 - Patients shut out of process leading to the release of revised guidelines by the Patented Medicine Prices ...
Posted by Michael Wonder on 14 Oct 2020
Evidence for HTA: innovative methods for challenging times
13 October 2020 - Dalia Dawoud, Scientific Adviser at NICE Science, Evidence and Analytics Directorate explains NICE’s role as co-host of ...
Posted by Michael Wonder on 19 Aug 2020
Financing drug innovation in the US: current framework and emerging challenges
19 August 2020 - The current US drug innovation financing framework rests on the notion that a defined period of marketing ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 11 Aug 2020
Trump’s call for essential drugs to be made in US threatens innovation, says trade group
11 August 2020 - The trade group for the US pharmaceutical industry has warned that President Donald Trump’s latest executive ...
Posted by Michael Wonder on 10 Aug 2020
Australian start-ups push for bigger role in vaccine making
9 August 2020 - An Australian startup racing to develop a successful coronavirus vaccine has urged the federal government to ...
Posted by Michael Wonder on 26 Jul 2020
Debating drug prices in the shadow of coronavirus: access versus innovation. Can both sides win?
24 July 2020 - In fact, the pandemic has shown that both sides must win. ...
Posted by Michael Wonder on 21 Jul 2020
Harnessing real world data for regulatory use and applying innovative applications
22 July 2020 - A vast quantity of real world data are available to health care researchers. ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 22 Jun 2020
Proposed legislation to stabilise ACA threatens health care innovation
22 June 2020 - This week, the Democratic led House of Representatives may introduce legislation that seeks to stabilise the ...